Multiple Myeloma New Indication: Daratumumab for High-Risk Smoldering Myeloma Ulas D. Bayraktar, MD 2025-06-02
Multiple Myeloma New Reference: Talquetamab for Relapsed/Refractory Multiple Myeloma Ulas D. Bayraktar, MD 2025-04-07
Multiple Myeloma New Reference: Daratumumab with Lenalidomide and Bortezomib in 1st Line Multiple Myeloma Ulas D. Bayraktar, MD 2023-11-20
Multiple Myeloma New Indication: Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone for Untreated High-Risk Multiple Myeloma Ulas D. Bayraktar, MD 2023-09-23
Multiple Myeloma New Drug: Talquetamab-tgvs for relapsed or refractory multiple myeloma Ulas D. Bayraktar, MD 2023-06-07
